Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantAV
Atypical Ventures
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Atypical Ventures is Christopher Wake’s investment firm, associated with frontier-technology investing.
Recorded funding activity
Its recorded financings include Shennon Biotechnologies’ precision T-cell engagers for solid tumors, PhoenixAI’s analytical database for agents querying enterprise data, and Ventaris Surgical’s ureteroscopic system for kidney-stone clearance. The companies’ own announcements identify Atypical Ventures across these different technologies.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12M 1 disclosed · full round size, not this investor’s share